Mucosal IgG Interacts With Herpes Simplex Virus Glycoprotein E, an Fcγ Receptor Mimetic, and Neutralizes Viral Infection: Activity Is Reduced in the Setting of Vaginal Dysbiosis
- 31 July 2026
- journal article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Abstract
Background: Small studies have documented variable neutralizing activity of cervicovaginal lavage (CVL) against herpes simplex viruses (HSVs). This neutralizing activity is lower in women with bacterial vaginosis, a syndrome associated with HSV recurrences. However, the mechanisms have not been fully defined. Methods: We took advantage of a biobank of CVL and linked data including HSV neutralizing activity measured by plaque reduction assay, Nugent scores, and concentrations of CVL immune mediators. We fractionated CVL to enrich or deplete candidates and quantified neutralizing activity. Results: CVL reduced viral plaque formation by 40.82% ± 37.59% (mean ± SD, n = 361). Activity was independent of HSV serostatus, significantly lower in those with a Nugent score of 7 to 10 (n = 176, P < .05), and positively correlated with CVL concentrations of IgG (P = .001, n = 87) and human neutrophil peptides 1 to 3 (P < .001, n = 119). Activity was enriched in the immunoglobulin fraction but reduced when IgG, but not IgA, was depleted. Increasing concentrations of an anti–glycoprotein E monoclonal antibody overcame the neutralizing activity, suggesting that interactions between IgG Fc and glycoprotein E (gE), a viral Fc gamma receptor, contribute. Moreover, CVL had less HSV inhibitory activity against a gE-null virus. Treatment of CVL with peptide-N-glycosidase F, which cleaves IgG N-glycans, reduced HSV neutralizing activity. Conclusions: Interactions between IgG Fc and viral gE, independent of Fab specificity, contribute to cervicovaginal antiviral activity. Antiviral activity is reduced with dysbiosis, presumably reflecting lower IgG levels and differences in N-glycans that lead to decreased gE interactions. Results highlight the importance of developing and implementing strategies to protect against vaginal dysbiosis.Keywords
Funding Information
- National Institute of Child Health and Human Development
- National Institute of Allergy and Infectious Diseases
- National Center for Advancing Translational Sciences
- National Institutes of Health (R01HD098977)
- National Institutes of Health (2R01AI134367)
- National Institutes of Health (P30 AI124414)
- National Institutes of Health (UM1 AI068613)
- National Institutes of Health (UM1 TR004400)
This publication has 42 references indexed in Scilit:
- Antibody attributes, Fc receptor expression, gestation and maternal SARS-CoV-2 infection modulate HSV IgG placental transferiScience, 2023
- Neonatal Herpes Simplex Virus DiseaseClinics in Perinatology, 2021
- Rethinking mucosal antibody responses: IgM, IgG and IgD join IgANature Reviews Immunology, 2020
- The global roadmap for advancing development of vaccines against sexually transmitted infections: Update and next stepsVaccine, 2016
- Structure of FcγRI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG bindingProceedings of the National Academy of Sciences, 2015
- IgG in cervicovaginal mucus traps HSV and prevents vaginal Herpes infectionsMucosal Immunology, 2014
- Fcγ receptors as regulators of immune responsesNature Reviews Immunology, 2008
- Synergistic Copathogens — HIV-1 and HSV-2New England Journal of Medicine, 2007
- Association between Acquisition of Herpes Simplex Virus Type 2 in Women and Bacterial VaginosisClinical Infectious Diseases, 2003
- Impairment of the Mucosal Immune System: IgA and IgM Cleavage Detected in Vaginal Washings of a Subgroup of Patients with Bacterial VaginosisThe Journal of Infectious Diseases, 1998